Beacon Biosignals has raised an oversubscribed $86 million Series B to accelerate the clinical adoption of AI-powered biomarkers for neurological and psychiatric disease, expand its precision medicine data platform, and scale its neurodiagnostic infrastructure. The financing was backed by Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, S32, Catalio Capital Management, and Takeda, with continued participation from General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures. This new capital brings the company’s total funding to over $121 million.
Headquartered in Boston, Beacon Biosignals has developed a clinically validated neurotechnology ecosystem that captures and analyzes real-world brain activity using FDA-cleared wearable EEG devices. At the center of its platform is the Waveband device, a medical-grade wearable that measures electrical brain activity during sleep and wake states. By extending gold-standard EEG monitoring into the home, Beacon enables large-scale, ecologically valid data collection across diverse patient populations.
The data generated from these devices fuel Beacon’s large-scale foundation model of brain activity, which has been trained on millions of hours of EEG. This model identifies early disease signatures, predicts treatment response, and provides quantitative, objective biomarkers of brain function that can be used throughout clinical development and patient care.
The new funding will support the expansion of the Beacon Platform, which combines clinically validated EEG signals with advanced AI analytics to generate actionable biomarkers. Sleep has become a central focus within the platform, providing a consistent window through which neurological and psychiatric disorders can be studied. Many conditions, including Parkinson’s disease, Alzheimer’s disease, clinical depression, and sleep apnea, show distinctive patterns in sleep-related brain activity, making this data essential for precision diagnostics and therapeutic development.
Beacon now supports research and development initiatives with more than half of the world’s top ten biopharmaceutical companies. Its growing network of partners, including Takeda, UCB, and Syndeio, leverages AI-derived biomarkers to accelerate CNS drug pipelines, refine patient selection strategies, establish quantitative clinical endpoints, and detect disease progression earlier in development cycles.
The Series B also builds on Beacon’s recent acquisition of CleveMed’s home sleep-testing technology, which has added airflow, oxygen saturation, and respiratory monitoring capabilities to the company’s offerings. The combined ecosystem now represents one of the most comprehensive integrated platforms for analyzing sleep and brain function in both clinical and research environments.
Beacon’s long-term vision is to make brain function measurable and actionable at a population scale, bridging the gap between neurological data, therapeutic development, and clinical care. The company believes that precision neuroscience, enabled by real-world sleep and EEG monitoring, may have the same transformative impact on CNS disorders as biomarkers and molecular profiling have had on oncology and immunology.
KEY QUOTES
“Our mission is to make brain function measurable and actionable at scale. By training AI on millions of hours of real-world brain data, we’re beginning to map the signals of health and disease in ways that can accelerate drug development and ultimately improve how patients are diagnosed and treated.”
Jacob Donoghue, MD, PhD, CEO and Co-Founder, Beacon Biosignals
“For too long, neurology and psychiatry have lacked the kind of objective biomarkers that revolutionized other areas of medicine. Beacon’s ability to translate real-world sleep EEG into actionable insights brings that same precision to brain health, enabling more targeted, data-driven treatment development.”
Anthony Philippakis, MD, PhD, General Partner, GV
“We’re thrilled to partner with Beacon as they build the infrastructure for precision neuroscience. By connecting real-world brain data to both drug development and clinical care, Beacon is building a category-defining business positioned for sustained growth and broad impact in CNS therapeutics.”
Pavel Raifeld, CEO, Innoviva
